CSL.AX · ASX · Healthcare
CSL Limited
Also onConsensus Drift
Implied value per share
AUD 89.52
Market price
AUD 175.59
Implied upside
-49.0%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · USD model at 1.4042
Current EV/EBITDA of 22.6x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 16.6bn | USD 17.6bn | USD 18.7bn | USD 19.8bn | USD 21.0bn | +6.0% |
| EBIT | USD 3.1bn | USD 3.3bn | USD 3.4bn | USD 3.7bn | USD 3.9bn | +6.0% |
| NOPAT | USD 2.6bn | USD 2.7bn | USD 2.9bn | USD 3.1bn | USD 3.3bn | +6.0% |
| Add depreciation & amortisation | USD 1.1bn | USD 1.1bn | USD 1.2bn | USD 1.3bn | USD 1.4bn | +6.0% |
| Less capital expenditure | USD -1.5bn | USD -1.6bn | USD -1.7bn | USD -1.8bn | USD -1.9bn | +6.0% |
| Less increase in working capital | USD -944.6m | USD -1.0bn | USD -1.1bn | USD -1.1bn | USD -1.2bn | +6.0% |
| Free cashflow to firm | USD 1.2bn | USD 1.3bn | USD 1.4bn | USD 1.4bn | USD 1.5bn | +6.0% |
| Discount factor | 0.9647 | 0.8978 | 0.8356 | 0.7776 | 0.7237 | - |
| Present value | USD 1.2bn | USD 1.2bn | USD 1.1bn | USD 1.1bn | USD 1.1bn | -1.3% |
| Present Value Of The Forecast | USD 5.7bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.35% | Australian Government 10-year (RBA F2) |
| Equity risk premium | 6.00% | Market assumption |
| Beta | 0.414 | Reported 0.125, pulled toward 1.0 (Blume) |
| Cost of equity | 7.83% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.35% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 84.3bn | 88.5% of capital |
| Total debt | USD 10.9bn | 11.5% of capital, book value as a proxy |
| Tax rate | 15.8% | Effective, capped at statutory |
| WACC | 7.45% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
86% of EV
- Forecast FCFF, final year
- USD 1.5bn
- Capex at depreciation, working capital in reinvestment
- USD 3.3bn
- Less reinvestment at g/ROIC (29.6% of NOPAT)
- USD -965.7m
- Capitalised
- USD 2.3bn
- ROIC (reported)
- 8.4%
- Terminal value, undiscounted
- USD 47.6bn
- Terminal value, discounted
- USD 34.4bn
- Enterprise value
- USD 40.1bn
- Less net debt
- USD 9.4bn
- Equity value
- USD 30.7bn
Exit at 20.0x EBITDA
93% of EV
- Terminal value, undiscounted
- USD 104.7bn
- Terminal value, discounted
- USD 75.8bn
- Enterprise value
- USD 81.5bn
- Less net debt
- USD 9.4bn
- Equity value
- USD 72.1bn
Spread between methods: 80%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.45% | 105.57 | 113.20 | 123.31 | 137.42 | 158.61 |
| 6.45% | 78.78 | 82.00 | 85.96 | 90.97 | 97.59 |
| 7.45% | 61.07 | 62.31 | 63.75 | 65.45 | 67.51 |
| 8.45% | 48.51 | 48.79 | 49.07 | 49.35 | 49.63 |
| 9.45% | 40.24 | 40.48 | 40.72 | 40.96 | 41.20 |
Outlined: this model. Green text: above today's price of 125.05. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 6.0% | 25.2% | +19.2pp |
| EBIT margin | 18.4% | 30.1% | +11.7pp |
| Discount rate | 7.4% | 5.4% | -2.0pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.